Clinical Trial Update: Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing imatinib mesylate and dasatinib in previously untreated chronic phase chronic myeloid leukemia, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myeloid Leukemia, BCR-ABL1 Positive | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2012-07-10